Valion Bio (VBIO) Cost of Revenue (2021 - 2026)
Valion Bio (VBIO) posted quarterly Cost of Revenue of $7000.0 for Q4 2025, down 98.33% year-over-year from $419000.0 in Q4 2024, and down 97.59% quarter-over-quarter from $291000.0 in Q3 2025.
Valion Bio (VBIO) Cost of Revenue (2021 - 2026) Analysis & Trends
Valion Bio's Cost of Revenue history runs 5 years deep, the most recent figure standing at $7000.0 for Q4 2025.
- In Q4 2025, Cost of Revenue fell 98.33% year-over-year to $7000.0; the TTM figure through Dec 2025 stood at $350000.0 (down 55.01% YoY), while the FY2025 annual figure was $350000.0, down 55.01% from the prior year.
- Cost of Revenue for Q4 2025 stood at $7000.0, down from $291000.0 in the prior quarter.
- The five-year high for Cost of Revenue was $419000.0 in Q4 2024, with the low at $7000.0 in Q4 2025.
- The 5-year median for Cost of Revenue is $296000.0 (2021), against an average of $242650.0.
- Peak annual rise in Cost of Revenue reached 254.88% in 2025, while the deepest fall reached 98.33% in 2025.
- Valion Bio's Cost of Revenue stood at $391000.0 in 2021, then declined by 6.65% to $365000.0 in 2022, then retreated by 3.56% to $352000.0 in 2023, then rose by 19.03% to $419000.0 in 2024, then sank by 98.33% to $7000.0 in 2025.
- Business Quant data shows VBIO's Cost of Revenue at $7000.0 in Q4 2025, $291000.0 in Q3 2025, and $32000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 93.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 174.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 298.26 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 387.98 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 67.21 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Valion Bio | 405,599.63 | -1.79 Mn | -45,000.00 | 6,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6,000.00 |
| Jun 30, 2026 | 6,000.00 |
| Dec 31, 2025 | 7,000.00 |
| Dec 31, 2025 | 7,000.00 |
| Sep 30, 2025 | 291,000.00 |
| Sep 30, 2025 | 291,000.00 |
| Jun 30, 2025 | 32,000.00 |
| Jun 30, 2025 | 32,000.00 |
| Mar 31, 2025 | 20,000.00 |
| Mar 31, 2025 | 20,000.00 |
| Dec 31, 2024 | 419,000.00 |
| Dec 31, 2024 | 419,000.00 |
| Sep 30, 2024 | 82,000.00 |
| Sep 30, 2024 | 82,000.00 |
| Jun 30, 2024 | 110,000.00 |
| Jun 30, 2024 | 110,000.00 |
| Mar 31, 2024 | 167,000.00 |
| Mar 31, 2024 | 167,000.00 |
| Dec 31, 2023 | 352,000.00 |
| Dec 31, 2023 | 352,000.00 |